Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of CP-COV03 in mild or moderate COVID-19
KCT0007307Phase 2Completed
- Sponsor
- Hyundai Bioscience
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niclosamide in coronavirus disease 2019 (COVID-19), sponsored by Hyundai Bioscience. Started May 2022; status: completed.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0007307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007307.